Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support

Critical Reviews in Oncology/Hematology

Volumn 72, Issue 3, 2009, Pages 265-269

  Brugger, W ^a   Bacon, P ^b   Lawrinson, S ^c   Romieu, G ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b AMGEN INC   (United States)

^c AMGEN LTD   (United Kingdom)

^d CENTRE VAL D AURELLE   (France)

Author keywords

Breast cancer; Chemotherapy; Elderly; Febrile neutropenia; G CSF; Pegfilgrastim; Primary prophylaxis

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT THERAPY; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG RESPONSE; ELDERLY CARE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FILGRASTIM; HUMANS; NEUTROPENIA;

EID: 71549166629     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.05.002     Document Type: Review

References (22)

1. Muss H.B., Woolf S., Berry D., et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293 (2005) 1073-1081
2. Wildiers H., Kunkler I., Biganzoli L., et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 8 (2007) 1101-1115
3. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., and Lyman G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106 (2006) 2258-2266
4. Kuderer N.M., Dale D.C., Crawford J., and Lyman G.H. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25 (2007) 3158-3167
5. Dees E.C., O'Reilly S., Goodman S.N., et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 18 (2000) 521-529
6. Link B.K., Budd G.T., Scott S., et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 92 (2001) 1354-1367
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
8. Bonadonna G., Moliterni A., Zambetti M., et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330 (2005) 217
9. Chirivella I., Bermejo B., Insa A., et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 114 (2009) 479-484
10. Crawford J., Ozer H., Stoller R., et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325 (1991) 164-170
11. Trillet-Lenoir V., Green J., Manegold C., et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A (1993) 319-324
12. Aapro M., Cameron D.A., Pettengell R., et al. EORTC guidelines for the use of granulocyte colony stimulating factor to reduce the incidence of chemotherapy induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42 (2006) 2433-2453
13. Smith T.J., Khatcheressian J., Lyman G.H., et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24 (2006) 3187-3205
14. Johnston E., Crawford J., Blackwell S., et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18 (2000) 2522-2528
15. Bhana N. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review. Curr Opin Oncol 19 (2007) 328-335
16. Romieu G., Clemens M., Mahlberg R., et al. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Crit Rev Oncol Hematol 64 (2007) 64-72
17. Godwin J.E., Kopecky K.J., Head D.R., et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031). Blood 91 (1998) 3607-3615
18. Harousseau J.L., Witz B., Lioure B., et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 18 (2000) 780-787
19. Maher D.W., Lieschke G.J., Green M., et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 121 (1994) 492-501
20. Meza L.A., Green M.D., Hackett J.R., Neumann T.A., and Holmes F.A. Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin. Pharmacotherapy 23 (2003) 1424-1431
21. Usuki K., Urabe A., Masaoka T., et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol 116 (2002) 103-112
22. Repetto L., Biganzoli L., Koehne C.H., et al. EORTC cancer in the elderly task force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39 (2003) 2264-2272